Resources Repository
-
ReportPublication 2017DCP3: Improving Health and Reducing Poverty
This report from the World Bank is the ninth and final volume of the Disease …
This report from the World Bank is the ninth and final volume of the Disease Control Priorities, Third Edition (DCP3) series. It provides an overview of the findings and methods explored in the first eight volumes, placing them within a framework that identifies an efficient pathway toward essential universal health coverage through the implementation of 21 essential packages that include health interventions and fiscal and intersectoral policies. The Disease Control Priorities Network (DCP) promotes and…
Cost-Effectiveness Analysis | Health Systems | Infectious Diseases | Costing Methods | Health Outcomes | Evidence Synthesis | Benefit-Cost Analysis | Maternal/Reproductive Health | Child/Nutrition | Chronic Disease/Risk | Mental Health | Injuries/Accidents | Social Determinants | Policy/Regulation | Global Governance | Economics/Finance | Government/Law | Health/Medicine | Science/Technology | Global -
ReportPublication 2017DCP3: Major Infectious Diseases
This report from the World Bank is the sixth volume of the Disease Control Priorities, …
This report from the World Bank is the sixth volume of the Disease Control Priorities, third edition (DCP3) series and examines the burden of infectious diseases, which remain a leading cause of death globally, especially for children and adolescents. This report identifies feasible and cost-effective platforms to prevent and treat diseases like HIV/AIDS, other sexually transmitted infections, tuberculosis, malaria, adult febrile illness, viral hepatitis, and tropical diseases. This volume also emphasizes the importance of addressing…
Cost-Effectiveness Analysis | Health Systems | Infectious Diseases | Costing Methods | Health Outcomes | Evidence Synthesis | Global Governance | Economics/Finance | Health/Medicine | Global -
ReviewPublication 2016Review: CEA for Maternal, Newborn, Child Health
This chapter summarizes the findings of a systematic search of the cost-effectiveness literature on interventions …
This chapter summarizes the findings of a systematic search of the cost-effectiveness literature on interventions to improve reproductive, maternal, newborn, and child health. Interventions for newborn health, treatment of febrile illness, immunization against preventable diseases, and micronutrient interventions remain among the most cost-effective and affordable. Other studies explore how to provide existing interventions using new platforms to increase outreach or decrease cost per person covered, or both. Interventions provided in the community may achieve both purposes to…
Cost-Effectiveness Analysis | Health Systems | Infectious Diseases | Priority Setting/Ethics | Costing Methods | Maternal/Reproductive Health | Child/Nutrition | Education/Labor | Health/Medicine | Global -
ReportPublication 2015Chapter 4: Cervical Cancer
This chapter focuses on the possibility of primary prevention of cervical cancer as a result …
This chapter focuses on the possibility of primary prevention of cervical cancer as a result of the introduction of two commercially available vaccines against human papillomavirus (HPV). Few low- and middle-income countries (LMICs) have initiated or sustained cytology-based cervical cancer prevention programs, and these countries experience very high incidence and mortality rates. Fortunately, alternative strategies to prevent cervical cancer have been investigated and extensively evaluated in these settings. The authors report findings from cost-effectiveness analyses…
Cost-Effectiveness Analysis | Health Systems | Infectious Diseases | Mathematical Models | Chronic Disease/Risk | Clinical Care | Health/Medicine | Science/Technology | Global -
ReviewPublication 2015Medicare's Use of CEA for Prevention (But Not Treatment)
Medicare currently pays for 23 preventive services in its benefits package, the majority of which …
Medicare currently pays for 23 preventive services in its benefits package, the majority of which were added since 2005. In the past decade, the program has transformed from one essentially administering treatment claims, to one increasingly focused on health promotion and maintenance. What is largely unappreciated is the role cost-effectiveness analysis has played in the coverage of preventive services. This study reviews the role of cost-effectiveness analysis in Medicare coverage of preventive services and contrast it…
Cost-Effectiveness Analysis | Health Systems | Infectious Diseases | Priority Setting/Ethics | Technology Assessment | Child/Nutrition | Chronic Disease/Risk | Policy/Regulation | Economics/Finance | Government/Law | Health/Medicine | North America -
ReviewPublication 2013Role of Health Economic Analyses in Vaccine Decision Making
Beginning in the 20th century with the consideration of the seven-valent pneumococcal conjugate vaccine in …
Beginning in the 20th century with the consideration of the seven-valent pneumococcal conjugate vaccine in the US, cost effectiveness became a topic of discussion when a vaccine was being considered for universal use by the US Advisory Committee on Immunization practices (ACIP). In 2008, the ACIP began using formal criteria for the presentation of such data and their inclusion in ACIP discussions. More recently, the U.S. Institute of Medicine has recommended that health economic considerations play a…
Cost-Effectiveness Analysis | Health Systems | Infectious Diseases | Priority Setting/Ethics | Economics/Finance | Health/Medicine | North America -
ReviewPublication 2003Public Health Policy and Cost-Effectiveness Analysis
This chapter presents an overview of the uses for cost-effectiveness analysis and disease-simulation modeling to …
This chapter presents an overview of the uses for cost-effectiveness analysis and disease-simulation modeling to rigorously evaluate alternatives to reduce mortality from cervical cancer. Scientific advances have provided opportunities over time to revisit strategies for cervical cancer prevention. How to invest health resources wisely, such that public health benefits are maximized-and opportunity costs are minimized-is a critical question in the setting of enhanced cytologic screening methods, human papillomavirus DNA testing, and vaccine development. Developing sound…
Cost-Effectiveness Analysis | Health Systems | Infectious Diseases | Mathematical Models | Chronic Disease/Risk | Policy/Regulation | Health/Medicine | Global -
ReportPublication 2022Investment Case for New Tuberculosis Vaccines
Investing more financial resources to accelerate scientific progress toward an effective tuberculosis (TB) vaccine will …
Investing more financial resources to accelerate scientific progress toward an effective tuberculosis (TB) vaccine will save lives, fight antimicrobial resistance, advance health equity, improve economic growth, and bring a substantial return on investment. This World Health Organization (WHO) report describes the full value proposition for new TB vaccines. These analyses articulate the broader economic impacts of new TB vaccines to guide global stakeholders when making investment decisions for novel TB vaccines and to plan for…
Cost-Effectiveness Analysis | Infectious Diseases | Economics/Finance | Health/Medicine | Global -
ReviewPublication 2022Systematic Review of Economic Evaluations of COVID-19 Interventions: Non-Health Impacts and Distributional Issues
The authors conducted a systematic review of economic evaluations of COVID-19 interventions and assessed whether …
The authors conducted a systematic review of economic evaluations of COVID-19 interventions and assessed whether they incorporated non-health impacts and distributional concerns. Among the 70 articles included, more than half (56%) included at least one non-health impact, although only 21% incorporated non-economic consequences. Only 17% examined subgroups of interest. The median ICER for the entire sample was $67,000/quality-adjusted life-year (QALY) (interquartile range [IQR] $9000-$893,000/QALY). Interventions including a pharmaceutical component yielded a median ICER of $93,000/QALY (IQR…
Cost-Effectiveness Analysis | Infectious Diseases | Evidence Synthesis | Social Determinants | Culture/Society | Economics/Finance | Health/Medicine | North America